The C terminus of nuclear hormone receptors is a complex structure that contains multiple functions. We are interested in the mechanism by which thyroid hormone converts its receptor from a transcriptional silencer to an activator of transcription. Both regulatory functions are localized in the ligand binding domain of this receptor superfamily member. In this study, we have identified and characterized several functional domains within the ligand binding domain of the human thyroid hormone receptor (TR␤) conferring transactivation. Interestingly, these domains are localized adjacent to hormone binding sites. One activation domain, designated 4, is only 17 amino acids in length and is localized at the extreme C terminus of TR. Deletion of six amino acids of 4 resulted in a receptor that could still bind hormone but acted as a constitutive silencer, indicating that 4 is required for both transactivation and relief of the silencing functions. In addition, we performed in vivo competition experiments, the results of which suggest that in the absence of 4 or hormone, TR is bound by a corepressor protein(s) and that one role of hormone is to release corepressor from the receptor. We propose a general model in which the role of hormone is to induce a conformational change in the receptor that subsequently affects the action of 4, leading to both relief of silencing and transcriptional activation.
The thyroid hormone receptor (TR) belongs to the superfamily of nuclear hormone receptors which includes receptors for steroids, retinoids, and vitamin D 3 . These receptors act as transcription factors which activate gene expression in a ligand-dependent manner. Unlike receptors for the classical steroid hormones, TR is not associated with heat shock proteins in the absence of hormone but is bound to its response element and actively represses promoter activity through a mechanism termed silencing (27, 32) . Like other nuclear hormone receptors, TR activates expression of target genes in the presence of hormone (5, 12) .
Nuclear hormone receptors, like other transcription factors, are composed of modular functional domains which can act as functional units outside of their natural context. As an example, the entire C terminus of the glucocorticoid receptor was transferred to its amino terminus without affecting its transcriptional properties (31) . Such an approach also led to the identification of the transactivation domains 1 in the glucocorticoid receptor N terminus and 2, localized C terminal of the DNA binding domain (DBD) (24) . The amino termini of some receptors contain an activation domain, which retains normal function when linked to a heterologous DBD such as that of the yeast transcription factor GAL4 (7, 24, 36) . Similarly, the entire C termini of various receptors have been fused to the GAL4 DBD, resulting in hormone-dependent transcription factors (4, 7, 24, 43) . GAL-receptor fusions act similarly to wild-type receptors when bound to a GAL4 DNA-binding site. The structures of various other transcription factors have been analyzed by using GAL4 DBD fusions, and the results have led to the general conclusion that transcription factors have a modular structure (18) .
Interestingly, if the C terminus of TR, retinoic acid receptor (RAR), or v-erbA is fused to the GAL4 DBD, the resulting fusion protein is able to silence the activity of a promoter containing a GAL4 response element (17-mer) (4, 10) . Thus, a strong silencing domain exists that is analogous to a transactivation domain. Indeed, TR is able to silence transcription from a minimal promoter by inhibiting the formation of a preinitiation complex, suggesting that silencing is mediated through the basal transcriptional machinery (6, 16) . We have recently demonstrated that the ligand binding domain (LBD) of TR interacts with TFIIB in a hormone-dependent manner (3) . In the absence of hormone, the LBD of TR binds to TFIIB, and this interaction may serve to sequester or freeze TFIIB in an inactive conformation. Nevertheless, the interaction of TR with TFIIB is not sufficient for silencing, since other regions of TR which do not interact with TFIIB (the N-terminal portion of the LBD) are also required (3) .
In this report, we identified three functional activation units, termed 2, 3, and 4. These domains are within the C terminus of the receptor and are localized adjacent to hormone binding sites. We also performed competition or squelching experiments analogous to those of Gill and Ptashne which suggested the existence of adaptor or coactivator molecules that are required for the function of transactivators (21) . We show that the silencing activity of TR was greatly reduced by coexpression of either the C terminus of v-erbA or the LBD of TR, suggesting the existence of a cellular corepressor(s) which is limiting within the cell. Interestingly, the ability of the LBD of TR to compete for the putative corepressor(s) is reduced in the presence of hormone, suggesting that corepressor has reduced affinity for the liganded receptor. We also show that one of the identified activation domains, 4, which is positioned at the extreme C terminus of TR, is required for hormone to release the corepressor. Deletion of 4 resulted in a receptor which retained the ability to bind hormone but acted as a constitutive silencer. Of interest is the fact that this region is also deleted in the v-erbA oncogene product, a constitutive silencer. Our data suggest that hormone binding itself is not sufficient to relieve silencing function. We propose a model by which hormone binding affects 4 and together the two events lead to relief of receptor-bound cellular corepressor. Subsequently, the activation domains are exposed and transcriptional activation ensues.
MATERIALS AND METHODS
Oligonucleotides and plasmids. Sequences of the oligonucleotides used are given in Table 1 .
The GAL4 (amino acids 1 to 147) constructs and the expression vector ⌬gal have been previously described (4) . The human RAR␣ expression vector has been described previously (20) . pABgal 94 linker was constructed by deleting the GAL4 coding sequences with SmaI and HpaI of pABgal 1-147 and inserting a synthetic oligonucleotide, AGAATTCCC, to provide the same reading frame of the multiple cloning site. Transferring coding sequences from pABgal-hTR␤ (6) into pABgal 94 linker by using SmaI and HindIII resulted in pABgal 94-hTR␤. pABgal 94 TR 168-259 was created by transferring the coding sequences from pABgal TR 168-259 with XmaI-HindIII (6) . The expression plasmids GAL-TR 260-456 and GAL-TR 408-456 were created by inserting the HindII-HindIII fragment or the PmlII-HindII fragment of pABgal 94 hTR␤ into pABgal 94 linker digested with and HindIII and PvuII. pABgal 94 TR 307-377 was constructed by inserting the Sau3A fragment of peA101 (44) Band shift assays. COS cells (10 6 ) were cotransfected with 10 g of expression vectors by the Polybrene method (14) . Miniscale extract preparations and band shift experiments were performed as described elsewhere (7).
Cell culture. Cell culture was done as described in Baniahmad et al. (6) . For transfection experiments in both CV1 and L cells, 5 g of reporter (17-mer tkCAT⌬H/N) (4) and 1 to 2 g of receptor were used for a 100-mm-diameter dish. For competition experiments, 5 g of reporter, 200 to 300 ng of receptor, and 10 g of competitor DNA were used. For pABgal-TR⌬C6-VP16, 20 to 100 ng was added to the cells. All experiments were performed a minimum of three times.
Limited proteolytic digestion analysis. Protease digestion of GAL-TR and GAL-TR⌬C6 was carried out as described previously (1, 26) .
Hormone binding. The hormone binding assay was done as described previously (28) , with a few minor modifications. Essentially, 10 l of in vitro-translated receptor proteins was incubated with 125 I-labeled thyroid hormone (T3; Dupont) in T3 binding buffer (44) at 4ЊC overnight; 300 l of reaction mixture was then loaded on a G-25 column (Boehringer Mannheim Biochemicals) to separate the receptor-bound ligand from the free ligand. K d was determined by Scatchard analysis.
RESULTS

Multiple activation domains in the C-terminal half of TR.
To identify amino acid sequences which are involved in the transactivation function, we analyzed natural mutations of TR. The syndrome of generalized resistance to thyroid hormone (GRTH) is due to mutations in the gene coding for human TR␤ (hTR␤) (38) . Alignments of published mutations of the receptor show that one group is clustered close to the Cterminal end as illustrated in Fig. 1A and another cluster is located in the central part of the LBD. An additional receptor mutant isolated from a patient with GRTH was found to be located in the area of the hinge or D region, which is also required for hormone binding (26) . Mutant receptors which have lost or have a decreased affinity for hormone (38) either are less active in target gene activation or are constitutive silencers (6) . Similar to v-erbA, the mutations may alter transactivation properties in addition to hormone binding. Based on our current understanding of (i) the size of the functional regions involved in modulating transactivation and (ii) the role of hormone as a trigger of conformational changes in the receptor (1), we reasoned that it should be possible to dissect the C terminus into smaller functional units. Such units would be expected to lose hormone binding but might act constitutively as transcriptional enhancers.
To analyze the putative activation domains and to distinguish whether the above-listed mutations affect only hormone binding, we used the yeast GAL4 DBD (amino acids 1 to 94 [GAL1-94]), which contains dimerization and nuclear localization functions, thus eliminating possible interpretation problems on receptor mutations affecting these functions. We constructed various GAL4 DBD receptor deletion mutants and cotransfected them into both CV1 and L cells together with a reporter containing a single GAL4 DBD upstream of the thymidine kinase promoter-chloramphenicol acetyltransferase gene reporter (4) . As expected, fusion of the complete C terminus of hTR␤ to the GAL DNA-binding site led to a protein which repressed basal promoter activity in the absence of hormone (Fig. 1A) . Upon addition of thyroid hormone (T3), it activated reporter gene expression in both CV1 and L cells, similarly to the wild-type receptor (6) . This finding confirms that the LBD of TR is a functional and independent module.
In localizing the transactivation domains, we first examined the N-terminal region, where one mutation of GRTH is located. As shown in Fig. 1A , we found a weak but significant transactivation function in the vicinity of this mutation (TR amino acids 207 to 217). Next, we concentrated on the central region, which contained a cluster of mutations in GRTH (TR amino acids 307 to 368). As shown in Fig. 1A , this fragment showed significant transactivation activity. Various receptor deletion mutants were generated to map the precise location of the activation domain(s) in this area. As shown in Fig. 1A , deletion across this C-terminal fragment resulted in a gradual decrease of its transactivational activity. The results suggest that amino acids between 307 and 368 are important for transactivation. In contrast, deletion from the N terminus down to 339 had no significant effect on transactivation. The transactivation function is localized between amino acids 339 and 368 which is adjacent to the area of clustered mutations. Therefore, natural mutations in GRTH patients are not localized within the transactivation domain but upstream of it. Both N-terminal and central regions of the TR LBD have transactivation functions. On the basis of homologies in position relative to the previously identified transactivation domain of the glucocorticoid receptor 2 (24), we refer to these two regions as 2 and 3.
A conserved stretch of 17 amino acids at the C-terminal end of TR is a functional and separable activation domain. To define transactivation functions in the extreme C-terminal end, where another cluster of natural mutations was detected, we performed a similar deletion analysis of human TR␤ in this region. Again, cotransfection experiments were performed in CV1 cells and mouse fibroblast L-cell lines. Deletion of regions from amino acids 168 to 408 or 168 to 260 of the TR LBD (TR 260-456 and TR 408-456) led to loss of activation of the reporter construct (Fig. 1B) . In contrast, further deletion (TR 440-456), which retained only the last 17 amino acids, showed strong transactivation function in both cell types. Further deletion of eight amino acids (TR 448-456) diminished activity, whereas further deletions abolished activation. The results show that the C terminus of TR contains another activation function; this transactivation function was named 4. The 4 region, which is highly conserved in the nuclear hormone receptor superfamily (see Fig. 3A ), has been shown to play an essential role in the transactivation functions of TR, RAR, and the estrogen receptor (ER) (13, 33, 45) .
Our observation leads to several conclusions and suggestions. (i) The overall activation is weaker than that of the entire TR LBD, which suggests that all activation domains (2, 3, and 4) contribute to the overall transactivation capacity of the TR LBD. (ii) These activation domains are localized close to regions which are known to be involved in hormone binding through analysis of natural mutations and their hormone binding affinities. (iii) Although the C-terminal 17 amino acids are also present in the longer deletion mutants (TR 408-456 and TR 260-465), they did not exhibit transactivation. We reasoned that this may be due to a repressor function located nearby. Such a repressor function could be mediated at an intramolecular level by stabilizing a specific folding, which upon addition of hormone is altered in the wild-type receptor (1). Alternatively, the repressor function could be due to interaction with a repressor protein(s) which does not allow proper exposure of the activation domain. Of course a combination of these possibilities could occur.
Characterization of the identified activation domains 3 and 4. Sequence alignment of the central activation domainconserved acidic residues resulted in a weak activator, whereas in L cells, changing the two aspartic acid residues in the Nterminal half was sufficient to eliminate its function. This finding suggests that the conserved acidic amino acids play a crucial role in mediating activation function either by directly interacting with a target or by maintaining a proper structure of this activation domain.
Similarly, alignment of the extreme C-terminal sequences of VOL. 15, 1995 MECHANISM OF THYROID HORMONE RECEPTOR SILENCING 79 TR (4) with other members of the nuclear hormone receptor superfamily shows a conserved positioning of proline residues and hydrophobic and acidic amino acids, as highlighted in Fig.  3A . The conserved stretch of amino acids is located at the C-terminal end of TRs, close to the end of RXRs and slightly more central in other receptors. Similarly, mutations were introduced in the conserved amino acids of the C-terminal 17-amino-acid activation domain 4 (Fig. 3B) . Interestingly, mutation of one of the most conserved amino acids, a glutamic acid at position 452 of hTR␤ (TR-1G), did not have an effect on gene activation in the cells tested. Likewise, the mutation of another glutamic acid at position 455 (TR-1A) showed no remarkable change in function. However, double mutations of conserved amino acids such as phenylalanine and aspartic acid (TR-2A) or glutamic acid and aspartic acid (TR-2R) showed reduced activity. Triple mutation of three conserved negatively charged amino acids completely destroyed activation function (TR-3A). To confirm that the various GAL-receptor constructs were indeed expressed, we prepared miniextracts derived from transiently transfected COS cells for qualitative band shift assays. We found that all mutant constructs express similar amounts of functional proteins and were capable of binding specifically to 17-mer GAL4 binding sites (data not shown). Thus, conserved amino acids in the transactivation domains 3 and 4 are important in mediating transcriptional activation. The extreme C-terminal amino acids of TR are required for relief of silencing. To test the role of hormone and the Cterminal conserved amino acids of 4 in relieving silencer function, we deleted the last six amino acids of TR, which are not required for hormone binding (26) , and generated GAL-TR⌬C6 (amino acids 168 to 450). Similar to our previous findings (26) , this receptor mutant is still able to bind to thyroid hormone (T3), since a protease-resistant receptor fragment can be detected after digestion of GAL-TR⌬C6 in the presence of T3 (Fig. 4A) (26) . The hormone binding affinity of GAL-TR⌬C6 was approximately 40-fold lower than that of GAL-TR (K d of 8.5 ϫ 10 Ϫ8 for GAL-TR⌬C6 versus 2.0 ϫ 10 Ϫ9 for GAL-TR) as determined by direct hormone binding (data not shown). Since the important amino acids required for transactivation in 4 are deleted, we expected that hormone might relieve silencing but should not lead to full activation. Cotransfection experiments demonstrated that the truncated receptor indeed has silencing function without hormone, but in contrast to the full-length hormone binding domain construct (GAL-TR 168-456), the addition of hormone even to 10 Ϫ5 M, a concentration which should saturate all mutant receptors, did not lead to relief of silencing (Fig. 4B) . Thus, the deletion of six amino acids resulted in a constitutive silencer, although the receptor still retains the ability to bind hormone. The hormone binding and protease-resistant conformation change induced by hormone are not sufficient to relieve silencing. We conclude that 4 activation domain not only participates in activation but also is required to relieve silencing.
To test whether relief of the silencing function is based on removal of a corepressor protein, we performed cotransfection experiments in which we used GAL-TR⌬C6 as a silencer protein and overexpressed the C-terminal domain of v-erbA in CV1 cells. These C-terminal sequences (amino acids 362 to 639) have been shown previously to exhibit constitutive silenc- (6) . Shown in Fig. 4B as fold repression, the coexpression of the v-erbA C terminus resulted in complete loss of silencing function by TR⌬C6. Since it contained no DBD, the effect appears likely to result from protein-protein interactions of v-erbA with a cellular corepressor. The inhibitory effect of coexpression of the C terminus of v-erbA is not due to a dominant negative effect caused by heterodimerization between the C terminus of v-erbA and GAL-TR⌬C6 (discussed with respect to Fig. 4E and 5 ). As controls, v-erbA had no significant effect on GAL1-94 target gene expression (Fig.  4B) , and no effects were observed with the empty expression vector (not shown). Similar results were obtained with L cells (data not shown). This finding suggests the presence of specific factors which interact with the C termini of both receptors.
Thus, the v-erbA C terminus is able to compete for cellular factors which participate in gene silencing by the TR LBD.
To generalize our conclusions, we tested various other GALreceptor fusions which are known to have silencing functions (GAL-hTR␤, GAL-v-erbA, and GAL-RAR) (4) in a similar type of experiment. Coexpression of the C terminus of v-erbA showed a strong ability to counteract the silencing function of each of these receptors (Fig. 4C ). These observations led us to the conclusion that a common factor(s) mediates the silencing function for this subclass of nuclear receptors. In a similar approach, the full-length RAR was used instead of the v-erbA C terminus, which shows moderate silencing in L cells in the absence of hormone (4) . Overexpression of RAR resulted in decreased repression of reporter construct by GAL-TR⌬C6 (Fig. 1B) 
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BANIAHMAD ET AL. MOL. CELL. BIOL. (Fig. 4D) ; no significant effect was noted on the promoter. Addition of retinoic acid again permitted greater silencing of the promoter by GAL-TR⌬C6, suggesting that a hormonebound receptor has less ability to compete for such a soluble corepressor. Similar results were obtained by using the fulllength C terminus of TR (Fig. 4D) . Addition of hormone significantly decreased the ability of the C terminus of TR to compete for the cellular corepressor activity. Also, coexpression of a mutant TR, the kindred S receptor (41) which does not bind hormone, relieves silencing (data not shown). These results are consistent with our hypothesis that the C terminus of TR interacts with a cellular corepressor and that one role of ligand is to cause the dissociation of corepressor(s) from the LBD, suggesting that in the wild-type receptor, the role of hormone and the 4 domain is to dissociate corepressor molecules from the receptor. Coexpression of COUP-TF did not significantly reduce the silencing activity of GAL-TR⌬C6, suggesting that COUP-TF does not interact with the putative corepressor (data not shown). Finally, to further investigate the role of the C-terminal activation domain 4, we examined whether it is exchangeable with a heterologous activation domain. We replaced 4 with the VP16 activation domain by fusion of VP16 sequences to GAL-TR⌬C6. This resulted in an extremely potent activator, which enhanced expression over 1,500-fold. However, this receptor construct was not hormone responsive even at 10 Ϫ5 M T3, suggesting that 4 functions cannot be replaced by a heterologous activation domain (Fig. 4E) . If a specific role of 4 is to relieve silencer function, we would expect this 4-deleted receptor-VP16 derivative to still bind the silencing factor(s) despite its strong activation. Indeed, the addition of the v-erbA C terminus led to an appropriate sixfold increase of transactivation. This observation supports a direct sequestering of receptor-bound repressors rather than some alternate mechanism by which the v-erbA C terminus inhibits DNA binding through heterodimerization with GAL-TR⌬C6. The latter mechanism should have resulted in a strong decrease of activation of the receptor-VP16 fusion.
Taken together, our data suggest that the putative repressor protein(s) was still bound by the mutated receptor-VP16 fusion despite the presence of the strong activation domain VP16 and hormone. In addition, the functional activation domain 4 cannot be replaced by a heterologous activation domain and must provide specific structural or functional characteristics. Just a six-amino-acid deletion of the conserved sequences renders the receptor into a constitutive silencer, although it is still able to bind hormone. Thus, the conserved C-terminal TR sequences, which are absent in v-erbA, have a dual function: to activate gene transcription and to dissociate repressor proteins from the receptor in the presence of hormone.
A relatively small region of TR competes for the corepressor. Previously, we postulated that two distinct regions of the C terminus of TR were required for silencing (3) . Two fragments of the C terminus (amino acids 168 to 259 and 260 to 456) were able to silence transcription even when expressed as separate GAL DBD fusions (9) . We demonstrated earlier that the role of the TR 260-456 fragment in transcriptional silencing may be to interact with TFIIB in a hormone-dependent manner (3); however, no functional role has been attributed to the more N-terminal fragment. To address the possibility that the TR 168-259 fragment interacts with the putative cellular corepressor(s), we examined the ability of the LBD and various fragments of the LBD of TR to compete for the corepressor. Cotransfection experiments were performed with GAL-TR as a silencer protein, and the LBD of TR (amino acids 168 to 456) or various fragments (amino acids 168 to 259 or 260 to 456) were overexpressed as competitors. As shown in Fig. 5 , coexpression of the entire LBD of TR results in a marked reduction of silencing function by TR. Interestingly, one of the receptor fragments, amino acids 168 to 259, competes for the corepressor as efficiently as the entire LBD of TR (Fig. 5) . However, the fragment containing amino acids 259 to 456 does not compete well for the corepressor (Fig. 5) . Thus, at least one corepressor appears to bind to a region of TR consisting of the N-terminal portion of the LBD.
DISCUSSION
The C terminus of steroid/thyroid hormone and retinoid receptors represents a unit of at least 300 amino acids in length which contains multiple functions. Clearly, gene transactivation is dependent on the binding of hormone. Analysis of the structures and functions of a large number of transcription factors suggests that activation domains are usually relatively small. Since the hormone binding function itself requires about 250 amino acids, and the vast majority of small deletions which abolish hormone binding also abolish transactivation, it has been extremely difficult to identify the precise functional subdomains conferring activation. Hormone is generally accepted VOL. 15, 1995 MECHANISM OF THYROID HORMONE RECEPTOR SILENCING 83
to induce a conformational change (1, 15, 26) , but the mechanism by which the conformational change leads to transcriptional activation is still unknown. As a working model, it is considered that hormone allows the exposure of activation domains. In the absence of ligand, different regions of the receptor which could bind corepressor molecules and, in the case of TR and RAR, lead to transcriptional silencing may be exposed. Further, we suggest that an important function of hormone is to prevent binding of corepressor molecules, so that activation domains can be exposed to a coactivator(s) and/or to the basal transcriptional apparatus. Analysis of the TR LBD has led to the identification of three transactivation domains, designated 2, 3, and 4 in accordance with the identified transactivation domains of the glucocorticoid receptor (24) . An activation domain (1) appears to exist in the N terminus of TR␤ and other receptors (20, 23, 25, 34, 37) . Interestingly, 2, 3, and 4 of TR are localized adjacent to sites required for hormone binding, as identified from patients with the phenotype of GRTH syndrome. Receptors isolated from these patients showed reduced or complete loss of hormone binding affinity. The close alignment of ligand binding sites and transactivation domains may be important or necessary for hormone action whereby ligand-induced conformational changes affect the transactivation state of nearby amino acids. Solution of the crystal structure of liganded and unliganded nuclear hormone receptors will be required for definitive insight into these structures.
Mutational analysis of conserved amino acids in the identified activation domains reveals that acidic residues are involved in mediating gene transactivation, although this does not exclude an important role for hydrophobic residues. Mutations which result in loss of function either may be based on structural change or may block protein-protein interactions with other factors. Our data suggest that hormone binding sites can be clearly distinguished from sites of transactivation function and that the majority of naturally occurring mutations affect only hormone binding. Mutational analysis of conserved amino acids in the mouse ER, homologous to 4 of TR, were performed by Danielian et al. (13) . Introducing a triple mutation into the wild-type receptor resulted in a receptor which bound hormone with similar affinity but showed reduced hormone-dependent activation. Mutation in this region coupled with deletion of the N-terminal transactivation domain resulted in an nonfunctional receptor, suggesting that the conserved region is involved in transactivation (13) . This transactivation domain has also been recently examined in TR␣ and RAR (33) . In agreement with our data, deletions in the C terminus of TR␣ result in a receptor which is unable to transactivate (33) . Introduction of point mutations with 4 of TR␣ also eliminated transactivation while only moderately reducing hormone binding affinity (33) . The results with ER and TR␣ are consistent with our findings which demonstrate directly an activation function for the conserved region and show that 4 is a distinct functional domain of TR.
The more novel and unexpected role of 4 in silencing is revealed by deletional analysis. Deletion of 4 (TR⌬C6) resulted in a receptor which has constitutive silencer activity. Since this molecule is still able to bind hormone and undergo protease-resistant conformational change (26) , the inability of hormone to relieve silencer activity of this mutant receptor indicates that 4 must play an additional role beyond transactivation. A potential role is revealed by competition experiments. The ability of overexpressed v-erbA, TR, and RAR to relieve silencing by GAL4-TR⌬C6 suggests the existence of a cellular corepressor(s). In the presence of hormone, the corepressor protein would remain bound to the 4-deleted receptor and silencer activity would be maintained. In contrast, fulllength RAR (Fig. 4C) or the LBD of TR (Fig. 4C) , which are able to compete for the corepressor in the absence of hormone, fail to bind the corepressor when hormone is present. Therefore, 4 plays a crucial dual role in receptor activation; it serves as an activation domain and as an element required for corepressor removal.
Our competition experiments reveal the region of TR which interacts with the corepressor. The receptor fragment containing amino acids 168 to 259 of TR competes for the corepressor as efficiently as the entire C terminus of TR, suggesting that this region is sufficient for binding of the corepressor. It is unlikely that the corepressor is the RXR, since the fragment containing amino acids 168 to 259 lacks the regions of TR required for heterodimerization (DBD and the heptad repeats) (2, 22) . In addition, coexpression of RXR has no effect on the silencing activity of TR (data not shown). It has also been demonstrated that addition of RXR has no effect on TR-mediated silencing in an in vitro transcription system (17) . Although the fragment containing amino acids 260 to 456 is unable to compete for corepressor binding, we have shown that this region is required also for the silencing function of native TR (3) . Previously, we demonstrated that neither of two halves of the C terminus of TR (amino acids 168 to 259 or 260 to 456) was able to silence when expressed by itself as a GAL4 DBD fusion protein; however, when both halves are coexpressed, the silencing activity of TR is reconstituted (3) . One function of the more C-terminal fragment (260 to 456) is to interact with TFIIB in the absence of hormone. It has been suggested that TR may silence genes by interacting with TFIIB and either sequestering or freezing TFIIB in an inactive state (3, 16) . When hormone is present, the C terminus of TR no longer interacts with TFIIB and the events leading to transactivation are allowed to proceed. In this study, we demonstrate that the TR 168-259 fragment competes for silencing activity, suggesting that this region is necessary and sufficient for interaction with the putative corepressor. Thus, the role of this fragment of TR may be to interact with a corepressor which acts in concert with the sequestration of TFIIB by another distinct TR fragment (amino acids 260 to 456) to silence transcription.
Our data are consistent with the following model. In the absence of hormone, distinct regions of TR interact with both a corepressor(s) and TFIIB. The N terminus of TR interacts with the C terminus of TFIIB in a hormone-independent manner, while the LBD of TR interacts with the N terminus of TFIIB in a hormone-dependent fashion (3). It is possible that the interaction of the LBD of TR with the N terminus of TFIIB blocks the interaction of the N terminus of TFIIB with the small subunit of TFIIF (RAP 30), thus inhibiting preinitiation complex formation. As shown in this study, a relatively small region of TR consisting of the hinge region and the N-terminal portion of the LBD competes for the corepressor. This complex consisting of the LBD of TR interacting with both TFIIB and a corepressor(s) is sufficient to silence transcriptional activity. Hormone binding induces a conformational change which causes both the corepressor(s) and TFIIB to be released from the C terminus of TR, allowing the events leading to activation to proceed. In the case of the mutant TR⌬C6, hormone binds the receptor but does not cause the release of corepressor; thus, this mutant is a constitutive silencer of gene activity. The precise role of the 4 activation domain in the conversion of TR from a silencer to an activator is unknown. However, it is possible that the conformational change induced by hormone is different between full-length and 4-deleted TR; thus, the corepressor is removed in one case but not the other. Alternatively, the 4 activation domain may serve as a binding site for a coactivator once the receptor has undergone the hormone-dependent conformational change. Binding of the coactivator may serve as a trigger to release the corepressor and TFIIB. Thus, deletion of 4 would result in a receptor which is not able to bind a coactivator and therefore is not able to remove the corepressor and TFIIB.
In summary, we have identified three activation domains in the C terminus of hTR␤ termed 2, 3, and 4. The silencing activity of hTR␤ is greatly reduced by coexpression of the C terminus of the v-erbA oncogene product or the LBD of hTR␤, suggesting the existence of a cellular corepressor(s) which is limiting within the cell. The ability of the LBD of hTR␤ to compete for the corepressor is reduced in the presence of hormone, indicating that liganded receptor is not associated with corepressor. The region of hTR␤ which competes with the corepressor lies in the N-terminal region of the LBD (amino acids 168 to 259). Interestingly, if the 4 activation domain of hTR␤ is deleted, the resulting mutant still binds hormone but is a constitutive silencer. This finding suggests that hormone binding itself is not sufficient to relive silencing function. We suggest that hormone binding alters the conformation of the receptor, allowing for 4 to mediate the release of receptorbound corepressor(s). Subsequently, the activation domains are exposed and transcriptional activation ensues.
